Manus Bio
Manus Bio develops and scales engineered microbial cell factories using precision fermentation to produce complex natural and bioalternative molecules. The company operates multi-site R&D and large-scale biomanufacturing facilities and offers end-to-end programs and standalone services for strain design, enzyme optimization, process development, analytical characterization, and commercial manufacturing for food, flavor & fragrance, materials, chemical, agricultural and pharmaceutical supply chains.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Fermentation-produced monk fruit sweetener (mogroside ingredient)
A high-intensity, zero-calorie sweetening ingredient produced by fermentation; described as water-soluble and suitable for beverage, dairy and other applications.
Fermentation-produced steviol glycoside (Reb M)
A high-purity steviol glycoside ingredient produced through fermentation for large-scale sweetener applications, positioned to improve supply resilience.
Fermentation-produced citrus-derived flavor and fragrance ingredients
Fermentation-produced citrus flavour and fragrance ingredients such as nootkatone and valencene intended to reduce reliance on agricultural extraction and improve sustainability.
Fermentation-produced monk fruit sweetener (mogroside ingredient)
A high-intensity, zero-calorie sweetening ingredient produced by fermentation; described as water-soluble and suitable for beverage, dairy and other applications.
Fermentation-produced steviol glycoside (Reb M)
A high-purity steviol glycoside ingredient produced through fermentation for large-scale sweetener applications, positioned to improve supply resilience.
Fermentation-produced citrus-derived flavor and fragrance ingredients
Fermentation-produced citrus flavour and fragrance ingredients such as nootkatone and valencene intended to reduce reliance on agricultural extraction and improve sustainability.
Services
End-to-end development program integrating discovery, cell-factory design, enzyme optimization, and pilot services to accelerate strain translation from lab to pilot scale.
Program to produce bioalternatives at commercial scale using in-house large-volume fermentation and downstream capabilities.
Computational and AI-augmented engineering of enzymes to improve biosynthetic efficiency and catalytic performance.
Strain construction and screening using optimized chassis and automated high-throughput workflows to produce precursor compounds at higher yield, rate and titer.
Process development from bench (250 mL) through pilot scales (up to ~3,000 L) including fermentation and downstream integration to de-risk scale-up.
Genome-scale engineering services to construct and optimize robust production strains suitable for industrial manufacturing and partner-led commercialization.
End-to-end development program integrating discovery, cell-factory design, enzyme optimization, and pilot services to accelerate strain translation from lab to pilot scale.
Program to produce bioalternatives at commercial scale using in-house large-volume fermentation and downstream capabilities.
Computational and AI-augmented engineering of enzymes to improve biosynthetic efficiency and catalytic performance.
Strain construction and screening using optimized chassis and automated high-throughput workflows to produce precursor compounds at higher yield, rate and titer.
Process development from bench (250 mL) through pilot scales (up to ~3,000 L) including fermentation and downstream integration to de-risk scale-up.
Genome-scale engineering services to construct and optimize robust production strains suitable for industrial manufacturing and partner-led commercialization.
Expertise Areas
- Cell factory engineering and chassis development
- Metabolic and pathway engineering
- Enzyme and protein engineering with computational methods
- Whole-genome and genome-scale strain engineering
Key Technologies
- Precision fermentation (pilot to commercial scale)
- Whole-genome / genome-scale engineering
- High-throughput automated screening platforms
- AI-driven protein/enzyme design
News & Updates
Exhibited fermentation-produced sweetener samples and product overviews at IFT FIRST 2026 in Chicago; samples available for formulation testing.
Announcement of commercial-scale production of a fermentation-produced monk fruit sweetener at the Augusta BioFacility; notes FEMA GRAS review completed and FDA GRAS notification in progress.
Announcement of planned ground-breaking for an artemisinin biomanufacturing facility to onshore production of a key medicine input and expand cGMP capability.
Founder testified about deploying AI on the factory floor to support domestic production of essential medicines and manufacturing resilience.
Program with University of Texas at Austin reported a programmed lysis approach that reduced mechanical separation energy by more than 50% at pilot scale.
Announcement of a commercial partnership to launch a fermentation-produced nootkatone ingredient with exclusive commercialization by the flavor partner while Manus retains manufacturing rights.
Exhibited fermentation-produced sweetener samples and product overviews at IFT FIRST 2026 in Chicago; samples available for formulation testing.
Announcement of commercial-scale production of a fermentation-produced monk fruit sweetener at the Augusta BioFacility; notes FEMA GRAS review completed and FDA GRAS notification in progress.
Announcement of planned ground-breaking for an artemisinin biomanufacturing facility to onshore production of a key medicine input and expand cGMP capability.
Founder testified about deploying AI on the factory floor to support domestic production of essential medicines and manufacturing resilience.
Program with University of Texas at Austin reported a programmed lysis approach that reduced mechanical separation energy by more than 50% at pilot scale.
Announcement of a commercial partnership to launch a fermentation-produced nootkatone ingredient with exclusive commercialization by the flavor partner while Manus retains manufacturing rights.